FAQs

Frequently Asked Questions
An important focus of our research has been to understand how the brain networks - that give rise to tics - could be effectively modified or controlled using non-invasive forms of brain stimulation to reduce tics.

We are aiming to launch the device called ‘Neupulse’ in 2026 following regulatory approval ensuring its compliance to all relevant safety, quality and regulatory requirements.

The device and associated accessories will be available to purchase via our website in each country / region once we have received regulatory approval there.

The device delivers a pattern of electrical pulses to the underside of the wrist which can be activated on demand. The stimulation interacts with the nerves and parts of the brain which cause tics. Neupulse provides relief and a way to manage the symptoms and discomfort associated with tics.

Our research has been conducted on individuals from the age of 12 years old and over and the data shows the stimulation is effective however it may not be suitable for everyone and is contraindicated for some medical conditions.

The UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome run by Neupulse, Nottinghamshire Healthcare NHS Foundation Trust and the University of Nottingham showed that people who received active stimulation experienced a significant reduction in the severity and frequency of their tics. On average they saw a reduction in tic frequency of more than 25% while they received stimulation.

After using the device for 4 weeks, people who received active stimulation experienced a reduction in their tic severity of more than 35%. In total 59% of the people who received active stimulation experienced a reduction in tic severity of at least 25% compared to baseline.

Residents in the United Kingdom can sign up to our Research Mailing List to express their interest in participating in our research.

Please note that there is no guarantee of being recruited to participate in our research.

We currently only have ethics approval to conduct research on participants who reside in the UK. This may change in the future as we expand so please keep an eye on our website for updates.

  • “All previous treatments that I have tried for Tourette Syndrome over the last 20+ years have been unsuccessful, and using the clinical trial stimulation device has provided me with the most successful and positive effects on my Tourette Syndrome of any treatment to date.”

    Trudi, participant in the UK clinical trial
  • “It's an approach that helped lower the intensity and frequency of my tics without any of the side effects I have had in the past from the different medications I have tried that just didn't seem to work.”

    Heather, participant in the UK clinical trial

Company number: 13198315 

Registered Office:
The Ingenuity Centre
University Of Nottingham Innovation Park
Triumph Road
Nottingham 
England
NG7 2TU

Privacy Notice       Cookies

Neupulse and Neutrack are registered trade marks of Neurotherapeutics Ltd

Website by Clifton Media

Tourettes Friendly Organisation
All members of the Neurotherapeutics team have completed training with Tourettes Action educating them about Tourettes Syndrome, thus have been awarded with the Tourettes Friendly Organisation badge recognised by Tourettes Action.
Medilink Midlands Awards
Back to Top
crossmenu